Form 13-F position report

REDHILL BIOPHARMA LTD

Reported by MORGAN STANLEY

RDHL CUSIP 757468103 Manager CIK 0000895421

Reported 0 shares, down 445,309 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2023
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 37 Through Q1 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 92000
2022-03-31 99000
2022-06-30 124000
2022-09-30 194000
2022-12-31 62477
2023-03-31 0
2023-03-31 1742
2023-06-30 721
2023-09-30 205
2023-12-31 842
2024-03-31 274
2024-06-30 134
2024-09-30 0
2024-09-30 1573
2024-12-31 13742
2025-03-31 34
2025-06-30 3496
2025-09-30 2
2025-12-31 0
2026-09-30 147

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for REDHILL BIOPHARMA LTD held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 306 +306 (0.0%) < 0.01% $147 2026-11-13
Q4 2025 Reduced 0 -1 (-100.0%) 0 $0 2026-02-13
Q3 2025 Reduced 1 -1,801 (-99.9%) < 0.01% $2 2025-11-14
Q2 2025 Added 1,802 +1,789 (13761.5%) < 0.01% $3,496 2025-08-15
Q1 2025 Reduced 13 -2,200 (-99.4%) < 0.01% $34 2025-05-15
Q4 2024 Added 2,213 +2,033 (1129.4%) < 0.01% $13,742 2025-02-14
Q3 2024 New 180 +180 (0.0%) < 0.01% $1,573 2024-11-14
Q3 2024 Reduced 0 -360 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 360 -156 (-30.2%) < 0.01% $134 2024-08-14
Q1 2024 Reduced 516 -60 (-10.4%) < 0.01% $274 2024-05-15
Q4 2023 Added 576 +175 (43.6%) < 0.01% $842 2024-02-13
Q3 2023 Reduced 401 -200 (-33.3%) < 0.01% $205 2023-11-15
Q2 2023 Added 601 +175 (41.1%) < 0.01% $721 2023-08-14
Q1 2023 New 426 +426 (0.0%) < 0.01% $1,742 2023-05-15
Q1 2023 Reduced 0 -445,309 (-100.0%) 0 $0 2023-05-15
Q4 2022 Added 445,309 +60,054 (15.6%) < 0.01% $62,477 2023-02-14
Q3 2022 Added 385,255 +242,697 (170.2%) < 0.01% $194,000 2022-11-14
Q2 2022 Added 142,558 +103,442 (264.4%) < 0.01% $124,000 2022-08-15
Q1 2022 Added 39,116 +3,596 (10.1%) < 0.01% $99,000 2022-05-13
Q4 2021 Added 35,520 +1,479 (4.3%) < 0.01% $92,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

41 managers reported REDHILL BIOPHARMA LTD for Q1 2023.

Managers reporting REDHILL BIOPHARMA LTD in Q1 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
IFP Advisors Inc Unchanged 300 0 < 0.01% $2,175 5 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -41,637 0 $0 18 qtrs
CIBC WORLD MARKET INC Reduced 0 -11,075 0 $0 8 qtrs
Federation des caisses Desjardins du Quebec Reduced 0 -159,217 0 $0 6 qtrs
D A DAVIDSON & CO Reduced 0 -10,500 0 $0 27 qtrs
The Goldman Sachs Group Inc Reduced 0 -17,861 0 $0 13 qtrs
UBS Group AG Reduced 0 -2,891 0 $0 34 qtrs
ROYAL BANK OF CANADA Reduced 0 -4,750 0 $0 25 qtrs
Citigroup Inc Reduced 0 -1,038 0 $0 12 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -1,942 0 $0 37 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2023
Filed
May 15, 2023
Filing type
13F-HR
Position type
SPONSORED ADS

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.